Page last updated: 2024-11-04

cyclobarbital

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cyclobarbital: was heading 1977-94 (see under BARBITURATES 1977-90); CYCLOBARBITONE, HEXEMAL, & TETRAHYDROPHENOBARBITAL were see CYCLOBARBITAL 1977-94; use BARBITURATES to search CYCLOBARBITAL 1977-94; short to intermediate duration barbiturate used as hypnotic and sedative [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5838
CHEMBL ID268164
CHEBI ID134957
SCHEMBL ID157224
SCHEMBL ID23533905
MeSH IDM0224832

Synonyms (69)

Synonym
BIDD:PXR0072
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohexen-1-yl)-5-ethyl-
cyclobarbital
52-31-3
5-cyclohex-1-en-1-yl-5-ethylpyrimidine-2,4,6(1h,3h,5h)-trione
D07323
cyclobarbital (inn)
ciclobarbital (tn)
inchi=1/c12h16n2o3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h6h,2-5,7h2,1h3,(h2,13,14,15,16,17
5-(1-cyclohexen-1-yl)-5-ethylbarbituric acid
barbituric acid, 5-(1-cyclohexen-1-yl)-5-ethyl-
5-(1-cyclohexen-1-yl)-5-ethyl-2,4,6(1h,3h,5h)-pyrimidinetrione
hexemalum
pralumin
5-ethyl-5-cyclohexenylbarbituric acid
tetrahydrophenobarbital
cyklodorm
amnosed
cyclobarbitone
2,4,6-(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohexen-1-yl)-5-ethyl-
namuron
cyclobarbital [inn]
cyclobarbiton
cyclobarbitalum [inn-latin]
pro-sonil
fanodormo
phanodorm
5-(1-cyclohexenyl)-5-ethylbarbituric acid
hexemal
cyclodorm
ciclobarbital [inn-spanish]
irifan
adorm
phanodorn
einecs 200-138-3
cyclobarbitonum
ethylhexabital
palinum
philodorm
cavonyl
cyclohexenyl-ethyl barbituric acid
sonaform
cyclobarbitol
CHEBI:134957
CHEMBL268164
5-(cyclohexen-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione
cyclobarbitone [ban]
unii-0m8a98ad9h
zyklohexenylaethylbarbitursaeure
cyclobarbitalum
ciclobarbital
0m8a98ad9h ,
cyclobarbital [inn:ban:nf]
hypnoval
cyclohexal
sonoform
praelumin
fanodorm
SCHEMBL157224
cyclobarbital [mart.]
cyclobarbital [mi]
cyclobarbital [who-dd]
WTYGAUXICFETTC-UHFFFAOYSA-N
DTXSID9022865
SCHEMBL23533905
Q416966
5-cyclohexenyl-5-a currencythyl-barbitursa currencyure
DB13737
2-ethyl-6-(furan-2-yl)-4,5-dihydropyridazin-3(2h)-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID38914Negative log of molar concentration (-log ED50) required to reduce cell division by 50% in Arbacia egg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID167611Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic); ND = No Data1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1130940Retention index of the compound by HPLC method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID169098Negative log of molar concentration (-log C) required to produce 50% inhibition of oxygen (oxygen uptake) on rat brain respiration in vitro; ND = No Data1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID26320pKa value is evaluated1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1130943Octanol-water partition coefficient, log P of nonionized form of compound1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1130945Inhibition of Arbacia egg cell division1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (71.43)18.7374
1990's0 (0.00)18.2507
2000's5 (23.81)29.6817
2010's1 (4.76)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.80 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index54.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]